Cytosorbents Co. (NASDAQ:CTSO) Sees Significant Increase in Short Interest

Cytosorbents Co. (NASDAQ:CTSO - Get Free Report) saw a large increase in short interest during the month of November. As of November 30th, there was short interest totalling 1,370,000 shares, an increase of 5.4% from the November 15th total of 1,300,000 shares. Based on an average daily volume of 123,700 shares, the days-to-cover ratio is currently 11.1 days.

Analyst Upgrades and Downgrades

CTSO has been the subject of a number of recent analyst reports. HC Wainwright reiterated a "neutral" rating and set a $1.00 price target on shares of Cytosorbents in a report on Monday, November 11th. StockNews.com started coverage on Cytosorbents in a report on Thursday. They issued a "hold" rating for the company.

Institutional Investors Weigh In On Cytosorbents

Several hedge funds and other institutional investors have recently modified their holdings of the company. Sargent Investment Group LLC grew its position in Cytosorbents by 13.4% in the 3rd quarter. Sargent Investment Group LLC now owns 1,626,247 shares of the medical research company's stock valued at $2,439,000 after purchasing an additional 192,747 shares during the period. CM Management LLC grew its holdings in shares of Cytosorbents by 3.0% during the second quarter. CM Management LLC now owns 850,000 shares of the medical research company's stock valued at $598,000 after buying an additional 25,000 shares during the last quarter. Geode Capital Management LLC increased its position in shares of Cytosorbents by 7.5% during the third quarter. Geode Capital Management LLC now owns 467,058 shares of the medical research company's stock worth $701,000 after acquiring an additional 32,415 shares in the last quarter. Finally, Atomi Financial Group Inc. acquired a new stake in shares of Cytosorbents in the 3rd quarter worth about $51,000. Institutional investors own 32.87% of the company's stock.

Cytosorbents Stock Down 9.9 %

CTSO traded down $0.10 during midday trading on Monday, hitting $0.91. The company had a trading volume of 209,458 shares, compared to its average volume of 126,238. The stock's 50 day moving average price is $0.97 and its 200 day moving average price is $1.02. Cytosorbents has a 52 week low of $0.70 and a 52 week high of $2.15. The company has a market capitalization of $49.74 million, a price-to-earnings ratio of -2.53 and a beta of 0.57. The company has a quick ratio of 1.58, a current ratio of 1.97 and a debt-to-equity ratio of 1.06.

About Cytosorbents

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.